Viking Therapeutics, Inc.

NASDAQ (USD): Viking Therapeutics, Inc. (VKTX)

Last Price

32.369

Today's Change

+0.85 (2.69%)

Day's Change

30.90 - 34.06

Trading Volume

6,046,567

Overview

Market Cap

3 Billion

Shares Outstanding

111 Million

Avg Volume

3,942,933

Avg Price (50 Days)

42.74

Avg Price (200 Days)

57.05

PE Ratio

-34.44

EPS

-0.94

Earnings Announcement

05-Feb-2025

Previous Close

31.52

Open

31.50

Day's Range

30.9 - 34.0694

Year Range

23.11 - 99.41

Trading Volume

6,046,567

Price Change Highlight

1 Day Change

2.70%

5 Day Change

-4.99%

1 Month Change

-24.53%

3 Month Change

-48.73%

6 Month Change

-38.98%

Ytd Change

-21.28%

1 Year Change

31.27%

3 Year Change

811.83%

5 Year Change

396.47%

10 Year Change

304.62%

Max Change

304.62%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment